JNJ · Earnings call · 2026Q3T · Full report

CARVYKTI Earlier-Line Adoption

JOHNSON & JOHNSON · 2026-10-13 · Importance 26 · Surprise 24

Johnson & Johnson said CARVYKTI is available in more than 20 markets and is gaining share in earlier-line multiple-myeloma settings. Approximately 50% of U.S. CARVYKTI utilization is in lines two and three, supported by physician familiarity, access, and reported overall-survival outcomes. The company is educating health care providers on earlier use, patient selection, bridging, and achieving high minimal-residual-disease negativity. Five-year CARTITUDE second-line follow-up showed approximately half of patients remained in complete remission without further treatment, according to management.

Key facts

• Johnson & Johnson stated CARVYKTI is available in over 20 markets.
• Johnson & Johnson said they are educating health care providers on CARVYKTI for earlier use with focus on appropriate patient selection, proper bridging, and achieving high levels of MRD negativity.
• Johnson & Johnson presented five-year follow-up data from the CARTITUDE study in the second line showing about half of those patients enjoyed complete remission out to five years with no further treatment.
• Johnson & Johnson said that roughly in the U.S., 50% of the utilization of CARVYKTI lies in lines two and three.